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First randomized clinical trials have demonstrated that stem cell therapy can improve cardiac recovery after the acute phase of
myocardial ischemia and in patients with chronic ischemic heart disease. Nevertheless, some trials have shown that conﬂicting
results and uncertainties remain in the case of mechanisms of action and possible ways to improve clinical impact of stem cells in
cardiac repair. In this paper we will examine the evidence available, analyze the main phase I and II randomized clinical trials and
their limitations, discuss the key points in the design of future trials, and depict new directions of research in this fascinating ﬁeld.
1.Concept andTypes ofRandomized
ClinicalTrials
A randomized clinical trial (RCT, also clinical study) is a
research study in human volunteers to answer speciﬁc health
questions. In other words, it is a rigorously controlled test
of a new drug or a new invasive medical device on human
subjects, in order to evaluate their eﬀectiveness and safety by
monitoring their eﬀects on large groups of people.
In the present state of clinical research, carefully con-
ducted RCT are the fastest and safest ways to ﬁnd treatments
that work in people and ways to improve health. Interven-
tional trials determine whether experimental treatments or
new ways of using known therapies are safe and eﬀective
under controlled environments. Observational trials address
health issues in large groups of people of populations in
natural settings.
All RCT must be conducted according to strict scientiﬁc
and ethical principles. Every clinical trial must have a
protocol, or action plan that describes what will be done in
the study, how it will be conducted, and why each part of the
study is necessary; including details such as the criteria for
patient participation, the schedule of tests, procedures, and
medications, and the length of the study.
RCTareconductedinaseriesofsteps,calledphases.Each
phase is designed to answer a separate research question.
(1) Phase I: researchers test a new drug or treatment in
a small group of people for the ﬁrst time to evaluate
its safety, determine a safe dosage range, and identify
side eﬀects.
(2) Phase II: the drug or treatment is given to a larger
group of people to see if it is eﬀective and to further
evaluate its safety.
(3) Phase III: the drug or treatment is given to large
groups of people to conﬁrm its eﬀectiveness, monitor
sideeﬀects,compareittocommonlyusedtreatments,
and collect information that will allow the drug or
treatment to be used safely.
(4) Phase IV: studies are done after the drug or treatment
has been marketed to gather information on the
drug’s eﬀect in various populations and any side
eﬀects associated with long-term use.
2. ClinicalResearch inStem Cell Therapy:
SameMethodology withaNewObjective
Recent advances in reperfusion strategies have dramatically
reduced early mortality after acute myocardial infarction2 Stem Cells International
(AMI), but as a result there is a higher incidence of heart
failureamongsurvivors.Optimalmedicaltherapyanddevice
implantation can improve the prognosis and the quality of
life of these patients. Nevertheless, mortality and rehospital-
ization rates are still high and entail an overwhelming cost.
The ﬁeld of cardiac cell therapy has emerged as a new
alternative in this situation, and has made rapid progress. Its
ﬁnalgoalistorepairthedamagedmyocardiumandtorestore
cardiac function. Nevertheless, this is a real therapeutic
challenge,giventhefactsthatthelossofcardiomyocytesafter
an AMI is in the order of 1 billion cells, that supporting cells
have to be supplied together with cardiomyocytes and that
environmental signals which guide stem cells to the cardiac
lineage or to the secretion of paracrine factors might be
absent in such a damaged tissue [1].
Studies evaluating this new approach during the last
15 years have overall succeeded to a greater or lesser
extent, and evidence available so far is encouraging. Phase
I and II RCT indicate that cell therapy is a safe treatment
which can improve cardiac function after AMI and in
the chronic phase of coronary artery disease (CAD). Trial
results are not uniform, however, probably due (1) to a lack
of standardization and optimization of cell isolation and
delivery protocols, (2) to a lack of a universally accepted
nomenclature and imprecise use of terminology, and (3)
to the large number of stem cell types under investigation
in diﬀerent clinical settings. These persisting mechanistic
uncertainties about stem cell therapy should not preclude
continuing clinical trials, which often provide the unique
opportunity of identifying issues missed by our suboptimal
preclinical models.
Moreover, these inconsistencies can be avoided or
reduced if classical scientiﬁc methodology is followed.
Although considered a relatively new ﬁeld of research, stem
cell experimentation must invariably walk on the path of
the scientiﬁc method. Since Erasistratus of Chios in the
third century before Christ and then after Aristotle’s time,
scientiﬁc method has been used as a way to ask and
answer scientiﬁc questions by making observations and
doing experiments. It includes a series of steps, that is,
(1) asking a question, (2) doing background research, (3)
constructing a hypothesis, (4) testing the hypothesis by
doing an experiment, (5) analyzing the data and drawing a
conclusion, and (6) communicating the results.
In the case of stem cell therapy, RCT started questioning
if there was a possibility of repairing the heart after diﬀerent
types of tissular damage. Background evidence has already
demonstrated that this possibility exists through stem cell
administration in several preclinical models of cardiomy-
opathy. Thus, the key points in the design of present and
future RCT in humans are (1) to formulate an adequate
hypothesis, (2) to select the ideal population, cell type, and
delivery method, and (3) to develop a correct and precise
protocol. These decisions must be made in the light of
previous evidence and with a translational mentality, in
which experimental/preclinical data should help to design
RCT, and, inversely, results of human studies should transfer
new questions and hypothesis to the laboratory/bench
side.
3. ClinicalScenariosinStem CellTherapy:
Evidence Available
Stem cell therapy has accumulated growing evidence in
diﬀerent physiopathological conditions in small and large
animal models, but human research has been almost limited
to CAD. In this paper we will focus on randomized placebo-
controlled clinical trials in humans (Tables 1, 2, 3,a n d
4). Nonetheless, we will comment only on the largest and
most relevant ones, as a way to analyze procedure-related
variables that could have determined treatment outcomes
and to address their limitations.
Natural history of CAD can be divided into acute (AMI)
and chronic phases (chronic ischemic heart disease). In the
latter stem cell therapy has been investigated in the subset of
(1) ischemic heart failure (ventricular dysfunction) and (2)
chronic myocardial ischemia (refractory angina).
In patients where restoration of contractile function is
the clinical goal—such as those with end-stage ischemic
heart failure or those early postinfarction—delivering cells
with contractile potential may be of high priority. Under
these conditions, naturally myogenic cells (i.e., skeletal
myoblasts, cardiomyocytes, or any progenitor cell driven
down a muscle lineage) appear to be a better ﬁrst choice.
However, on the one hand, formation of new myocardial
mass has only been strictly established for embryonic stem
cells (ESC), and is a process that has been achieved in very
few trials and in small percentages with adult stem cells.
And on the other hand, most of the studies after AMI have
used bone marrow mononuclear cells (BMMCs) as an easily
accessible source of adult stem and progenitor cells.
In conditions where chronic ischemia prevails, the
angiogenic potential of the cells seems a more reasonable
approach. In this case, BMMC, endothelial progenitor cells
(EPCs), vascular progenitor cells or blood-derived multi-
potent adult progenitor cells and mesenchymal stem cells
(MSCs) may be better choices than myogenic precursors.
3.1. Stem Cell Therapy after Acute Myocardial Infarction.
Several trials have evaluated stem cell therapy after AMI,
some with positive results and some with neutral ones. All of
them used the intracoronary route, once the patency of the
infarct-related artery was restored, and most of them with
the mononucleated fraction of the bone marrow (Table 1).
Four main RCT have been published with positive ﬁndings
so far. In the BOOST trial [3], BMMC were proved to
improve left ventricular (LV) contractility in the infarct
border zone and global LV ejection fraction (LVEF) by
6%. However, only patients with larger infarcts showed
maintained beneﬁts in terms of LVEF at long followup
(18 months). In the REPAIR-AMI trial [4], infusion of
BMMC promoted an increase in LVEF of 2.8% at 12
months. The FINCELL trial [8] reported an improvement
of 5% in LVEF after BMMC delivery. Finally, in the
REGENT trial [12], patients treated with BMMC and
with CXCR4+/CD34+ BMMC showed an increase of 3%
in LVEF which was not observed in the control group,
but these diﬀerences were not signiﬁcant between treated
and control patients at 6-month followup. This trial wasStem Cells International 3
Table 1: Randomized clinical trials with stem cells in patients with acute myocardial infarction (intracoronary delivery).
Trial (year) n Cell type Cell count Days after
AMI
Primary endpoint
(followup) Comments
Chen [2] (2004) 69 MSC 9 × 109 18 Improved LVEF at
6m LVEF by echocardiography
BOOST [3] (2004) 60 BMMC 2 × 109 6 ± 1 Improved LVEF at
6m
Eﬀect diminished after
18/61m
REPAIR-AMI [4]
(2006) 187 BMMC 2 × 108 3–6 Improved LVEF at
4m LVEF by ventriculography
Janssens [5] (2006) 66 BMMC 2 × 108 1 No change LVEF at
4m
Improved regional
contractility and reduction
in infarct size
ASTAMI [6]
(2006) 97 BMMC 7 × 107 6 ± 1 No change LVEF at
6m
LVEF ↑8% by SPECT, ↑1%
by MRI
TCT-STAMI [7]
(2006) 20 BMMC 4 × 107 1 Improved LVEF at
6m LVEF by echocardiography
FINCELL [8]
(2008) 77 BMMC 4 × 108 3 Improved LVEF at
6m LVEF by ventriculography
Meluzin [9] (2006) 66 BMMC 1 × 107 (low d)
1 × 108 (high d) 7
Improved LVEF at
3m in high dose
group
LVEF by SPECT
Penicka [10]
(2007) 27 BMMC 3 × 109 9 No change LVEF at
4m LVEF by echocardiography
HEBE [11] (2008) 189 BMMC versus PBC — 3–8
No changes in
global or regional
LV function
Final results pending
REGENT [12]
(2009) 117
BMMC
(unselected,
CD34+/CXCR4+)
2 × 108 (unsel),
2 × 106 (CD34+) 3–12 Improved LVEF
with both cell types
LVEF by MRI (in 117/200
patients)
MSC: mesenchymal stem cells (bone marrow origin); BMMC: bone marrow mononuclear cells; PBC: peripheral blood cells; LVEF: left ventricular ejection
fraction; LV: left ventricle; SPECT: single-photon emission computed tomography; MRI: magnetic resonance imaging.
limited by imbalances in baseline LVEF and by incomplete
followup.
On the other hand, three RCTs resulted in neutral
ﬁndings. Janssens et al. [5] reported no changes in LVEF
after BMMC infusion, but a reduction in the infarct volume
and an improvement in regional contractility in the greatest
transmural infarct cases were observed in treated patients.
In the ASTAMI trial [6] no signiﬁcant eﬀects on LVEF,
LV volumes, or infarct size were observed after BMMC
administration. The smaller number of cells and diﬀerences
in the cell isolation protocol were invocated to explain these
ﬁndings. Finally, in the HEBE trial [11], presented at the
AHA Scientiﬁc Sessions in 2008, no changes in global or
regional LV systolic function were reported after BMMC and
mononucleated cells isolated from peripheral blood.
So far, no safety concerns after BMMC intracoronary
infusion have emerged. The risk of a higher rate of instent
restenosis was not conﬁrmed in the FINCELL trial [8]
and in two recent meta-analyses [13, 14]. Moreover, none
of the trials reported an increased incidence of malignant
arrhythmias with BMMC [1].
Two trials have used MSC after AMI. The study by
Chen et al. [2] demonstrated an improvement in LVEF
and perfusion with intracoronary infusion of these cells,
but these results have not been duplicated. Hare et al. [15]
intravenously administered allogeneic MSC after an AMI
with no higher rate of MACE and some beneﬁts in terms of
LVEF.
New types of cells are also being explored, like adipose-
derived stem cells (ADSCs) (Figure 1). No evidence is avail-
able to date, but the ﬁrst-in-man RCT with intracoronary
administration of freshly isolated ADSC after AMI (the
APOLLO trial) has been recently completed.
Another approach for stem cell therapy after AMI is cell
mobilization from the bone marrow with the administration
of granulocyte colony-stimulating factor (G-CSF). Several
RCTs have been published, but results have been somehow
less encouraging (Table 2). Only three trials have reported
positive results. In the FIRSTLINE-AMI trial [16], the
RIGENERAstudy[17],andinthestudybyTakanoetal.[18],
signiﬁcant improvements in LVEF were observed. The rest of
the trials showed negative ﬁndings.
Finally, the MAGIC trials used a combination of G-CSF
and intracoronary injection of peripheral blood progenitor
cells. In the ﬁrst trial no diﬀerences in LVEF were noted,
and an increase in instent restenosis rate was observed (G-
CSF administration before bare-metal stent implantation)
[19]. Then the investigators changed the design and used4 Stem Cells International
Table 2: Randomized clinical trials with granulocyte colony-stimulating factor in patients with acute myocardial infarction (subcutaneous).
Trial (year) n Dose Timing after
AMI (PCI) Followup Comments
Valgimigli [28] (2005) 20 5μg/kg × 4d 1d No change LVEF at
6m LVEF by SPECT
FIRSTLINE-AMI [16]
(2005) 50 10μg/kg × 6d 90min Improved LVEF at
4m
LVEF by
echocardiography
REVIVAL-2 [29]
(2006) 114 10μg/kg × 5d 5d No change LVEF at
5m LVEF by MRI
STEMMI [30] (2006) 78 10μg/kg × 6d 28h No change LVEF at
6m
LVEF by
echocardiography and
MRI
G-CSF-STEMI [31]
(2006) 44 10μg/kg × 5d 35h No change LVEF at
3m LVEF by MRI
Ellis [32] (2006) 18 5μg/kg × 5d (lowd),
10μg/kg × 5d (highd) <30h Improved LVEF at
30d
LVEF by
echocardiography
RIGENERA [17]
(2007) 41 10μg/kg × 5d 5d Improved LVEF at
6m
LVEF by
echocardiography
Takano [18] (2007) 40 2,5μg/kg × 5d 1d Improved LVEF at
6m LVEF by SPECT
MAGIC [19] (2004)∗ 27 10μg/kg × 4d;PBC:1
× 109 1d No change LVEF at
6m LVEF by SPECT
MAGIC 3-DES [20]
(2006)∗ 50 10μg/kg × 3d;PBC:2
× 109 1d Improved LVEF at
6m LVEF by MRI
∗MAGIC trials used a combination of indirect mobilization (G-CSF) anddirect intracoronary injection of peripheral blood cells (PBC); LVEF: left ventricular
ejection fraction; SPECT: single-photon emission computed tomography; MRI: magnetic resonance imaging.
Table 3: Randomized clinical trials in patients with chronic ischemic heart failure.
Trial N Cell type Delivery Timing Primary endpoint Comments
MAGIC [21] 97 SM transepi >4w e e k s N oc h a n g eL V E F Reduction in
LVEDV/LVESV
Dib [22]2 3 S M t r a n s e n d o >10 years Improved LVEF and viability —
SEISMIC 47 SM transendo chronic No change LVEF —
TOPCARE-CHD [23] 58 BMMC versus CPC ic 81 ± 72 months Improved LVEF w/BMMC —
SM: skeletal myoblasts; BMMC: bone marrow mononuclear cells; CPC: circulating progenitor cells; transepi: tranepicardial; transendo: transendocardial; ic:
intracoronary; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume.
(a)
100µm
(b)
Figure 1: Autologous adipose-derived mesenchymal stem cells during mitosis (a) and growing in colonies in the 6th day of culture
(magniﬁcation ×10, (b)). These cells were expanded from the adipose tissue stroma-vascular fraction under good manufacturing practice
(GMP) conditions in our Cell Production Unit (Hospital Gregorio Mara˜ n´ on, Madrid).Stem Cells International 5
Table 4: Randomized clinical trials in patients with chronic myocardial ischemia.
Trial N Cell type Delivery Timing Primary endpoint Comments
Losordo [24]2 4 C D 3 4 + transendo chronic Improved angina parameters No clear perfusion beneﬁt
PROTECT-CAD [25] 28 BMMC transendo chronic Improved angina parameters Improved LVEF and
perfusion
Van Ramshorst [26] 50 BMMC transendo chronic Improved angina parameters Improved LVEF and
perfusion
BMMC: bone marrow mononuclear cells; LVEF: left ventricular ejection fraction.
Unipolar voltage Local linear shortening
Unipolar LLS 15mV
5mV
1- Final injection map
> 85 Tip
1- Final injection map
> 85 Tip
1cm 1cm
12%
6%
Figure 2: Electromechanical mapping of the left ventricle with the NOGA XP System (BDS, Cordis Corporation, Johnson and Johnson)
from a patient enrolled in the PRECISE trial in our centre. Myocardial areas with low contractility and impaired endocardial voltage are
identiﬁed as viable and targeted for cell injection (browndots).
drug-eluting stents. In the MAGIC 3-DES trial, positive
results in terms of LVEF were found after mobilization and
intracoronary injection of isolated cells [20].
3.2. Stem Cell Therapy for Chronic Ischemic Heart Disease
3.2.1. Ischemic Heart Failure. Skeletal myoblasts and BMMC
have been used in heart failure (HF) patients (Table 3).
T h eM A G I Ct r i a l[ 21], with transepicardial injection of SM
during coronary artery bypass grafting (CABG) surgery,
reported no changes in global or regional contractility.
However, a reduction in LV end-diastolic and end-systolic
volumes was observed in the high-dose group. Moreover, a
trend towards a higher incidence of ventricular arrhythmias
was noted. Dib et al. [22] reported an improvement in
LVEF and viability after SM transendocardial injection, in
contradiction with the SEISMIC trial (presented by Serruys
at the 2008 ACC meeting) which showed no beneﬁt of the
same procedure at 6 months.
In the TOPCARE-CHD trial [23], BMMC intracoronary
delivery into the coronary artery supplying the most dyski-
netic LV area showed an increase in LVEF of 2.9%, whereas
progenitor circulating cells infusion and controls did not
show any positive change. No major adverse cardiac events
(MACE) were reported in this trial.
3.2.2. Chronic Myocardial Ischemia. Patients with advanced
CAD and no further options of revascularization (“no-
option” patients) have also been studied in stem cell therapy
trials (Table 4). Three RCT have been completed using
the transendocardial route after electromechanical mapping
of the LV, with BMMC or blood-derived progenitor cells.
Losordo et al. [24] studied peripheral CD34+ cells isolated
after G-CSF injections. Angina frequency and exercise
time were improved, but no clear eﬀects on myocardial
perfusion were observed. In the PROTECT-CAD trial [25],
BMMC injections improved NYHA functional class, exercise
time, LVEF, wall thickening, and stress-induced perfusion
defects. Finally, Van Ramshorst et al. [26] reported better
LVEF, myocardial perfusion, angina functional class, exercise
capacity and quality of life after BMMC administration.
ADSC have also been studied in this type of patients.
The PRECISE trial is a prospective, double blind, RCT
that has randomised 27 patients with end-stage CAD not
amenable for revascularization and with moderate-severe
LV dysfunction to receive freshly isolated ADSC or placebo6 Stem Cells International
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Figure 3:Proposedmechanismsofstemcellfunctionafterhomingintothedamagedheart.Notethatdiﬀerentiationprocessesandparacrine
eﬀects activate a cascade of events that interact actively to create new blood vessels and cardiomyocytes, with the ﬁnal objective of functional
cardiac repair. CSCs: cardiac stem cells.
in a 3:1 ratio. The cells were delivered via transendocardial
injections after LV electromechanical mapping with the
NOGA XP delivery system (BDS, Cordis Corporation,
Johnson and Johnson) (Figure 2), and results are still waiting
for publication.
4. Key Issues for the Design of FutureStem
CellTherapy Trials
4.1. Ethical Considerations. As with any novel medical
intervention, with stem cell therapy there is an ethical
dichotomy between the need for new therapeutic approaches
and rigorous scientiﬁc evidence regarding the safety and
eﬃcacy of the procedures.
Due to its highly innovative nature, stem cell therapy
should focus on reducing risks and providing rigorous
evidence of eﬃcacy and safety. Fundamental ethical require-
ments in this case include an acceptable balance of beneﬁts
and risks, informed and voluntary consent and equitable
selection of subjects [27]. With transplantation of pluripo-
tent cells (i.e., ESC and induced progenitor cells), additional
safeguards are warranted because of the innovative nature
of these treatments, diﬀerences between animal and human
physiology, limited experience with these cells in humans,
and the high hopes of desperate patients for whom no
alternative eﬀective treatment currently exists.
Some speciﬁc ethical recommendations have been given
for RCT with stem cells [27]. They include the following.
(1) Phase I-II trials should enroll participants in late
stages of serious illness, such as persons with
advanced or refractory disease, but not so ill that they
are at greatly increased risk for adverse events.
(2) Use a proper control group, in order to evaluate the
positive eﬀects of treatment and to ascribe culpability
to any MACE seen with cell therapy. Then stem cells
can be oﬀered to the control group at the conclusion
of the trial if the results show short-term beneﬁt
(“cross-over”).
(3) Use clinically meaningful endpoints (see below,
Section 4.5).
(4) Coordinate scientiﬁc and ethical review, judging
the potential clinical beneﬁt of the treatment and
assessing the scientiﬁc justiﬁcation for the trial,
including proof-of-principle and preclinical data on
safety and dosage.
(5) Verify that participants clearly understand the fea-
tures of the trial. Since a comprehensive informed
consent form may not prevent misconceptions about
the trial, additional information should be given to
those patients with signiﬁcant misunderstandings.
Participants should appreciate that researchers may
not know whether or not the stem cell treatment will
be beneﬁcial, that animal studies might not predict
eﬀects of the cells in humans, and that unexpected
adverse events may occur.
(6) Ensure publication of results, even negative ones. For
the interest of patients, researchers, and sponsors,
negative ﬁndings cannot be withheld from publica-
tion.
4.2. Patient Selection and Delivery Methods. Patients with
larger AMI or with severely depressed baseline LVEF and
stroke volumes, or those with transmural extent of the
infarct seem to beneﬁt the most after BMMC treatment
[1].Conversely,patientswithmicrovascularobstructionmay
not respond to intracoronary infusion of cells. Therefore,
patient selection before conducting a RCT must take intoStem Cells International 7
account the pathophysiologic basis of the disease and
baseline characteristics of the patients. For instance, it is well
known that age, cardiovascular risk factors, and previous
heart failure have a negative impact on the potentiality and
functional capacity of the cells.
On the other hand, exploration of new delivery methods
is mandatory, due to the low rate of cell retention, engraft-
ment, and survival in the myocardium with the present
routes of administration. New devices include transcoronary
arterial injection into the perivascular space, improvements
intransendocardialinjectionneedledesign,andthefusionof
diﬀerent imaging techniques for a more precise delivery (i.e.,
X-ray/MRI suites used in conjunction with electroanatomic
maps of the LV).
4.3. Host Tissue and Cell-Related Issues. The two main
determiners of cardiovascular repair are stem cells and
injured myocardial tissue in which these cells are delivered.
Bothplaythecentralrolethatwillestablishtheeﬃcacyofthe
treatment, and knowledge of the molecular/cellular changes
andinteractionsbetweenthemiscrucialwhendesigningnew
RCT.
After AMI, if blood ﬂow is not restored quickly, cell
death and myocardial necrosis are deﬁnitive. This activates
a complement cascade with free radical and cytokine gen-
eration that recruits leukocytes and initiates the inﬂamma-
tory response. Inﬂammation, while potentially detrimental
to surviving cardiomyocytes, is necessary to clear away
the debris (clearance of necrotic cells) and orchestrate
downstreamhealingevents.Chronicinﬂammatorycellssuch
as macrophages and mast cells secrete cytokines and growth
factors, which in turn activate ﬁbroblasts to proliferate and
synthesize collagen, a major component of the scar that
replaces cardiomyocyte loss. Neovascularization is also stim-
ulatedbythereleaseofgrowthfactorsfromtheinﬂammatory
cells. Scar remodeling may continue for months to years,
depending on the extent of the initial ischemic event [33].
LV remodeling, deﬁned as post-AMI changes in wall
structure, chamber geometry, and pump function, is mainly
caused by changes in extracellular matrix (ECM). Car-
diac ECM not only supports and aligns cardiomyocytes,
thereby preserving a fundamental mechanical relationship
by which sarcomeric shortening is translated to muscle
force contraction, but also has signaling functions. Indeed,
ECM is a storage depot for growth factors, hormones, and
cytokines, and uses integrins to communicate with cells
[33]. All these functions are lost after myocardial ischemia
due to the release from inﬂammatory and endogenous cells
of matrix metalloproteinases (MMP) and cytokines. MMP
degrade ECM, disengage integrins, and stimulate reparative
ﬁbrosis. Cytokines like tumor necrosis factor α (TNF-α)a n d
interleukins like IL-1 and IL-6 induce MMP synthesis and
arerelatedtothedevelopmentofLVdysfunction,pulmonary
edema, endothelial dysfunction, and cardiomyocyte apopto-
sis [34].
These cellular and signaling processes that constitute the
proliferative phase of infarct healing in the myocardium
inﬂuence and determine the fate of implanted stem cells.
Ischemic myocardium constitutes an inﬂammatory hostile
environment for stem cells, which is devoid of nutrients
and oxygen and lacks survival signals from the ECM and
cell-to-cell interactions. Indeed, only a small fraction of
themsurvivesinsuchadverseconditions.Nevertheless,some
studies have shown that certain implanted stem cells may
improve or counteract this situation. Intramyocardial trans-
plantation of EPC after AMI induces signiﬁcant and sus-
tained increase in angiogenic, antiapoptotic, and chemoat-
tractant factors, that are upregulated in both transplanted
and host cells (i.e., vascular endothelial growth factor-A
[VEGF-A],ﬁbroblastgrowthfactor-2[FGF-2],angiopoietin-
1 [Ang-1], angiopoietin-2 [Ang-2], placenta growth factor
[PIGF],hepatocytegrowthfactor[HGF],insulin-likegrowth
factor-1 [IGF-1], platelet-derived growth factor-B [PDGF-
B], and stromal cell-derived factor-1 [SDF-1]) [35]. These
humoral factors provide an additional favorable milieu for
neovascularization and repair or regeneration of ischemic
myocardium. Furthermore, there is a cross-talk between the
heart and the bone marrow mediated by humoral eﬀects that
may improve this therapeutic eﬀect: it has been proved that
EPC transplantation further mobilizes endogenous BMMC
intoperipheralcirculation,recruitingthemintotheischemic
myocardium [35].
Having these considerations in mind, new lines of
research are being developed to improve cell survival rates
in the ischemic myocardium, between them [1] are the
following.
(1) Preconditioning of the myocardium to retain a
higher number of cells: low-energy shock waves,
ultrasound-mediated destruction of microbubbles in
the coronary circulation, and extracorporeal shock
wave treatment have proved to increase retention of
EPC, BMMC, and MSC. The last of these techniques
is undergoing clinical testing in the Cellwave trial.
(2) Activation or increase of chemotactic factors to
attractcells to the damaged area: high mobility group
box-1 (HMGB-1), SDF-1 or its receptor CXCR4, β2
integrin and endothelial nitric oxide synthase can be
activated to increase the rate of homing of diﬀerent
types of stem cells (i.e., progenitor blood cells, EPC).
Regarding stem cells administered to the myocardium,
their functional activity is determined by age and cardiovas-
cular risk factors. As a consequence, future phase II-III RCT
will explore cell enhancement strategies intended to increase
their therapeutic potential. Several strategies are currently
under investigation [1].
(1) Pretreatment of the patients with drugs to stimulate
cell potentiality: statins, rosiglitazone, and nitric
oxide synthase enhancer AVE9488 can improve the
migratory, invasive, and neovascularization capacity
of EPC.
(2) Strategies to prolong cell survival: between them,
the use of a combination of growth factors to
stimulate the expression of cardiomyocyte genes in
MSC (currently under clinical investigation in the
C-Cure trial), the use of heat shock to increase8 Stem Cells International
the resistance of cells to external stressors and the
pretreatment of ESC-derived cardiomyocytes with
heatshockandacocktailofsurvivalfactors,arebeing
explored.
(3) Genetic modiﬁcation of the cells prior to admin-
istration: overexpression of antiapoptotic genes or
genetic manipulation to maintain cell’s functionality
(i.e., capacity to secrete paracrine mediators, to
connect with host myocardium, or to diﬀerentiate
into specialized cardiac cell types) can be achieved
through genetic cell engineering.
(4) Combinedinjectionofcellsandbiomaterials:BMMC
encapsulationwithinscaﬀolds(epicardialpatches)or
peptide nanoﬁbers represents another strategy that
needs further investigation.
4.4. Mechanisms of Action. Nowadays, it is believed that stem
cell therapy could lead to successful cardiac regeneration
or repair by any or a combination of three main general
mechanisms (Figure 3): (1) diﬀerentiation of the adminis-
tered cells into all of the cellular constituents of the heart
(i.e.,cardiomyogenesisandvasculogenesisprocesses),or,less
probably, fusion of the administered cells with those, (2)
release of factors capable of paracrine signaling from the
administered cells, and (3) stimulation of endogenous repair
by injected cells, through stem cell cardiac niches activation
[36].
4.4.1. Cardiomyogenesis and Vasculogenesis. While in the
classic studies of the beginning of the decade (trans)
diﬀerentiation of BMMC into cardiomyocytes, smooth
muscle cells, and endothelial cells was postulated as the
main mechanism that might explain the cardiac recovery
resulting from stem cell therapy, this phenomenon has been
demonstrated in low proportions in more recent studies.
Regarding cellular fusion of administered cells with host
myocardial ones, to date there is little evidence to support
this hypothesis.
4.4.2. Paracrine Actions. Given that diﬀerentiation debate
is still ongoing and that the number of newly generated
cardiomyocytes and blood vessels is too low to explain sig-
niﬁcant functional improvements, the paracrine hypothesis
is now considered the most plausible. According to this
idea, the functional beneﬁts of stem cells might be related
to secretion of soluble factors that, acting in a paracrine
fashion, protect the heart, attenuate pathological LV remod-
eling, induce neovascularization, and promote regeneration
[37]. BMMC and MSC have been extensively studied and
proved to produce and secrete a broad variety of cytokines,
chemokines, and growth factors, between them VEGF, FGF,
HGF, IGF, adrenomedullin, thymosin β4 (TB4), SDF-1,
PDGF, and angiopoietin. These paracrine mediators are
expressed/releasedin atemporalandspatialmannerexerting
diﬀerent eﬀects depending on the microenvironment after
injury. In addition, these released factors may have autocrine
actions on the biology of stem cells themselves [37].
The paracrine factors may inﬂuence adjacent cells and
exert their actions via several mechanisms, including what
follows.
(1) Myocardial protection: MSC and BMMC in
an ischemic environment release cytoprotective
molecules that increase cardiomyocyte survival
(VEGF, FGF, HGF, IGF-1, TB4, SDF-1, PDGF, and
IL-1).
(2) Neovascularization: BMMC, MSC, and EPC can give
rise to vascular structures. The molecular processes
leading to angiogenesis and arteriogenesis involve
mediatorssuchnitricoxide,VEGF,SDF-1,FGF,HGF,
and angiopoietin.
(3) Cardiac remodeling: paracrine factors released by
transplanted stem cells may alter the ECM (i.e.,
inhibiting cardiac ﬁbroblast proliferation and types
I and III collagen synthesis), resulting in more
favorable post-AMI remodeling and strengthening
of the infarct scar. Stem cells (MSCs) may also
produce molecules that limit local inﬂammation,
thus reducing the remodeling process.
(4) Cardiac contractility and metabolism: it has been
demonstrated that stem cell therapy limits infarct
size and prevents LV dysfunction. On the other
hand,MSCandBMMCsecreteinotropicfactors(i.e.,
IGF-1) that positively modulate cell contractility,
and these cells attenuate the profound bioenergetic
abnormalitiesfoundintheborderzoneofmyocardial
infarction.
(5) Cardiac regeneration: as we have seen, diﬀerentiation
and cell fusion with native cardiomyocytes occur
in very low rates after stem cell administration.
Therefore, it is now believed that exogenous stem
cell transplantation may activate resident cardiac
stem cells (CSCs) and/or stimulate cardiomyocyte
replication via paracrine action. Factors secreted by
BMMC, MSC, and EPC, including HGF, SDF-1,
VEGF, and IGF-1, enhance proliferation, mobiliza-
tion, diﬀerentiation, survival, and function of CSC or
even restoration of cardiac stem cell niches.
4.4.3. Endogenous Repair. Finally, clonogenic and self-
replicating endogenous CSCs have been isolated and cul-
tured from human hearts. These CSCs—located in cardiac
stem cell niches—have the capacity to diﬀerentiate into
endothelial cells, smooth muscle myocytes, and cardiomy-
ocytes. Though insuﬃcient for a complete repair of the
myocardium after any kind of insult, these cells can be
activated by extracardiac delivered cells. Thus, administered
allogeneic MSCs participate in maintaining stem cell niches,
and through cell-to-cell interactions—apart from paracrine
eﬀects—may not only restore lost cellular constituents
(diﬀerentiation) but also these niches with an ongoing and
regulated self-replicating capacity [36].
4.5. Endpoints. Endpoints in RCT can be divided in hard
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as survival, disease free survival or improvement in objective
measures of disease-related functions, and are the ones
that can change medical practice and present guidelines.
The latter are deﬁned as parameters or physical signs used
as substitutes for an endpoint with clinical meaning that
measures the quality of life or mortality [38]. In other words,
they are intermediate markers (i.e., laboratory measure-
ments) or response variables that can substitute for a “true”
endpointforthepurposeofcomparingspeciﬁcinterventions
or treatments. Speciﬁcally, such response variables provide
some additional information on true endpoint occurrence
times for study subjects having censored values for such
times.
Hard or clinical endpoints have a direct relation with
prognosis and survival. They include all-cause death, cardiac
death, reinfarction, the need for further revascularizations,
readmission due to heart failure and stroke, taken indi-
vidually or as combined (composite) endpoints. Stem cell
therapy will join the therapeutic spectrum for cardiovascular
diseases only if it can be conﬁrmed to improve quality of life
and survival time with precise and accurate evidence of its
inﬂuence on these parameters. Indeed, clinical variables have
to be invariably the primary endpoints in large future phase
III RCT.
The only trials that have explored the eﬀect of stem
cells in hard endpoints have been the REPAIR-AMI trial
[4] and the BALANCE trial [39]. Both studies were not
powered to detect diﬀerences in this kind of parameters
(theywereconsideredassecondaryendpoints),andthelatter
was not even randomized. In the REPAIR-AMI trial the
cumulative endpoint of death, recurrent AMI or necessity
for revascularization was signiﬁcantly reduced in the BMMC
group compared with that in the placebo group after 12
months. Likewise, the combined endpoint of death, AMI
and hospitalization for heart failure was also reduced. In the
BALANCE study, BMMC transfer after AMI was associated
with a signiﬁcant reduction in mortality after 5 years of
followup. Moreover, in two large meta-analyses [13, 14],
a trend towards a beneﬁcial eﬀect of BMMC on death,
reinfarction and rehospitalization for heart failure has also
been reported.
Having said that, surrogate endpoints have been a
necessity with stem cell therapy RCT, because the sample
size required to have statistical power to detect diﬀerences in
mortality in these studies has been impractical [40]. For this
reason, and although they have been used in phase I studies
in order to do smaller and shorter trials, they should not be
the primary endpoints in phase II-III RCT.
Parameters used as surrogate endpoints to assess the
eﬀects of stem cell therapy on survival in ischemic heart
disease have to meet three requirements: (1) they must
be closely correlated with survival, (2) changes in the
parameters must reﬂect changes in the prognosis, and (3)
there must be a pathophysiological basis to account for
both relations [41]. Thus, there are several variables that
have been used as surrogate endpoints, basically imaging
(metabolism, perfusion, and contractility parameters) and
laboratory measurements.
4.5.1. Imaging Parameters. Many of the surrogate endpoints
used in clinical research on heart disease are parameters
obtained using imaging techniques, being LVEF the most
frequently used. Since sample size depends on the stan-
dard deviation of the surrogate endpoint to be measured
(which varies according to the variability of the imaging
technique), the higher the spatial and temporal resolution
of a given technique, the smaller the variability, especially if
quantiﬁcation is automatic [38]. Thus, techniques of choice
to quantify LVEF in stem cell RCT are magnetic resonance
imaging (MRI), single-photon emission computed tomogra-
phy(SPECT),andcontrast-enhancedechocardiography.The
same techniques are the ideal ones for a proper evaluation
of regional contractility (wall motion score index). Less
accurate tools include simple echocardiography, computed
tomography, and ventriculography.
However, if the study is conducted in patients who have
had AMI, it is essential to calculate infarct size and thickness
and thickening of the infarcted wall. For this purpose, MRI
(through delayed-enhancement of gadolinium sequences)
andSPECTarethebesttools.IfpatientswithdepressedLVEF
are included, we should use imaging techniques that appro-
priately measure LVEF and ventricular end-systolic and end-
diastolic volumes (i.e., MRI and contrast echocardiography).
Finally, if the study group consists of no-option patients,
imaging techniques should be employed that appropriately
assess myocardial perfusion (i.e., MRI and SPECT). In
all stages of ischemic heart disease metabolism can be
precisely studied by positron-emission tomography (PET) in
combination with SPECT data, but MRI also oﬀers relevant
information.
Another more experimental surrogate parameters inc-
lude the evaluation of microcirculation by gadolinium
delayed-enhancement, inotropic responsiveness with stress
(dobutamine) MRI, assessment of angiogenesis and arte-
riogenesis (ﬁrst-pass of gadolinium), and new techniques
of metabolic function, such as detection of high-energy
phosphate metabolism and blood-oxygen tension determi-
nation using blood-oxygen-level-dependent (BOLD) MRI
[40]. Again, in all these variables MRI plays a central role.
Nevertheless, despite all these robust imaging armamen-
tarium, current stem cell therapies (RCTs) are still limited by
theinabilitytoperformimagingatthecellularlevelandtrack
the fate of the cells (being radionuclide, MRI and reporter
gene techniques the most used). Thus, the development
of molecular imaging (with the use of MRI, PET, SPECT,
computed tomography and echocardiography) and better
techniques at the cellular level that allow 3-dimensional
imaging will be necessary for clinical applications in the
future[42].Finally,itisclearthatonlyRCTwithhardclinical
endpoints (i.e., cardiac death, reinfarction, rehospitalization,
revascularization, and stroke) will deﬁnitively establish the
role of stem cell therapy in ischemic heart disease. In this
regard, we must not forget that imaging cannot provide a
substitute for clinical outcome data.
4.5.2. Laboratory Parameters. Several laboratory measure-
m e n t sh a v eb e e nu s e da ss u r r o g a t e si ns t e mc e l lt h e r a p y
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heart failure are the most frequently used. Between them,
C-reactive protein (CRP), creatine-phosphokinase (CPK), T
and I troponin, and probrain natriuretic peptide (pro-BNP)
are universally available. Cytokines such as interleukins, and
growth factors have also been used.
4.6. Followup. Another key point is ﬁnal followup. Long-
term followup should be carried out and speciﬁed in all RCT
protocols in stem cell therapy, in order to precisely deﬁne
the safety of the procedure (i.e., oncogenesis, restenosis, late
adverse events).
4.7. The Consensus of the Task Force of the European Society
of Cardiology for Future Trials: Next Directions. The Task
Force of the European Society of Cardiology on stem cells
and repair of the heart was created in 2006 to investigate
and regulate the role of progenitor/stem cell therapy in the
treatment of cardiovascular disease. It was almost four years
ago that this group of experts and opinion leaders stated the
type of studies needed [43].
(1) Further large, double-blind, controlled RCT for the
use of autologous BMMC in the treatment of AMI.
Thepatientpopulationshouldbeallthosepresenting
within 12 hours of AMI and treated with immediate
revascularization, be it primary angioplasty or ﬁbri-
nolysis.
(2) Double-blind, controlled RCT for the use of autol-
ogous BMMC in the treatment of AMI in those
patients presenting late (>12 hours) or who fail to
respond to therapy (candidates for “rescue” angio-
plasty).Although,thesegroupsmayrepresentasmall
proportion of all patients with AMI, their prognosis
remains poor.
(3) Double-blind, controlled RCT for the use of autol-
ogous BMMC or SM in the treatment of ischemic
heart failure. At some stage, the role of autologous
stem/progenitor cells in the treatment of cardiomy-
opathies (in particular, dilated cardiomyopathy) will
need to be examined.
(4) A series of well-designed small studies to address
safety or mechanism to test speciﬁc hypotheses (i.e.,
studies with labelled cells or to investigate paracrine
or autocrine mechanisms). Such hypotheses would
have arisen from basic science experiments.
(5) Studies to conﬁrm the risk/beneﬁt ratio of the use of
cytokines alone (i.e., G-CSF) or in conjunction with
stem/progenitor cell therapy.
This Task Force also underlined the necessity for studies
with hard clinical endpoints, MACE, subjective beneﬁt and
economic gain [43]. Another key point is standardiza-
tion, both in outcome measures and in the processing
of cells (better achieved in specialized centers following
Good Manufacturing Procedure routines), in order to derive
meaningful comparisons. Since these trials will need to
include thousands of patients, they should be multicentre
and ideally pan-European. An example of this new phase III
large-scale trials is the RCT conducted by Zehier’s group in
Frankfurt, that will enroll up to 1200 patients with extensive
AMI (LVEF <40%) and with a combined primary endpoint
of cardiac death, reinfarction and rehospitalization due to
heart failure. On the other hand, the Task Force stated that
small uncontrolled trials with BMMC should be avoided, as
they are unlikely to add anything new to the ﬁeld.
Finally, next directions of cardiac cell therapy include
what follows.
(1) The study of the array of bioactive molecules that are
secreted by stem cells, which have been demonstrated
to induce neovascularization, modulate inﬂamma-
tion, ﬁbrogenesis, cardiac metabolism, and con-
tractility, increase cardiomyocyte proliferation and
activate resident stem cells. The exhaustive analysis
of this “secretomes” of BMMC, MSC, or EPC would
lead to a better understating of the mechanisms of
action of the cells and to a hypothetical protein-
based therapy (oﬀ-the-shelf, noninvasive, systemic,
and repetitive administration).
(2) The use of diﬀerent sources of pluripotent stem cells,
like ESC, spermatogonial stem cells and oocytes.
A new era has been initiated with the possibility
of reprogramming adult cells (skin ﬁbroblasts) to
a pluripotent state by retroviral transduction [44,
45]. These “induced-pluripotent stem cells” (iPSs)
show the characteristics of ESC and can diﬀerentiate
to cardiomyocytes. New retroviral vectors and even
nonviral vectors have been developed to reduce the
risk of mutagenesis, and genetic modiﬁcation of cells
with suicide genes have been proposed to reduce the
risk of tumor formation.
(3) The creation of bioartiﬁcial hearts after a process
of decelularization with detergents, obtention of the
underlying extracellular matrix (cardiac architec-
ture), and stem cell repopulation [46]. The “acellu-
lar”heartcanthenbereseededwithcardiacstemcells
or EPC, showing contractile activity in animal mod-
els. This new approach of tissue bioengineering has
opened a fascinating era in cardiovascular medicine.
5. Conclusions
Although mixed results have emerged from the ﬁrst stem
cell therapy RCT in cardiovascular medicine, the overall data
suggest that these procedures are feasible and safe in both
acute and chronic scenarios of ischemic heart disease. After
phase I-II RCT, it is clear that BMMC transfer after AMI has
the potential to improve the recovery of LV systolic function
beyond what can be achieved by current interventional and
medical therapies. In chronic ischemic heart disease, SM and
BMMC have proved to improve myocardial perfusion and
contractile performance.
New types of cells (including ADSC and iPS), improve-
ments in delivery and imaging methods, strategies to
enhance cell potentiality or to improve the myocardial
proinﬂammatory microenvironment, and the creation ofStem Cells International 11
bioartiﬁcial hearts are the main new directions of research
in the near future.
Finally, large-scale, phase III, double-blind, controlled
RCT performed under rigorous safety standards are being
initiated to prove unequivocal clinical beneﬁts, including
improved survival. These trials will deﬁnitively establish
the eﬀectiveness of stem cell therapy in improving clinical
outcomes, conﬁrming the real potential of cardiac regenera-
tive therapy.
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